COPD: Cardiopulmonary disease?

European Respiratory Journal

Volumn 41, Issue 6, 2013, Pages 1241-1243

  Kawut, Steven M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOPULMONARY DISEASE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; EDITORIAL; HEART FAILURE; HUMAN; LUNG DISEASE; MORBIDITY; MORTALITY; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; WORLD HEALTH ORGANIZATION; CARDIOVASCULAR DISEASES; CHEMISTRY; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK; TREATMENT OUTCOME;

CARBON MONOXIDE;

CARBON MONOXIDE; CARDIOVASCULAR DISEASES; HUMANS; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK; TREATMENT OUTCOME;

EID: 84878803112     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00009413     Document Type: Editorial

References (26)

1. Freimer N, Sabatti C. The human phenome project. Nat Genet 2003; 34: 15-21. (Pubitemid 36548781)
2. Hegele RA, Oshima J. Phenomics and lamins: from disease to therapy. Exp Cell Res 2007; 313: 2134-2143. (Pubitemid 46842978)
3. Lanktree MB, Hassell RG, Lahiry P, et al. Phenomics: expanding the role of clinical evaluation in genomic studies. J Investig Med 2010; 58: 700-706.
4. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604.
5. Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013; 41: 1292-1301.
6. Freixa X, Portillo K, Paré C, et al. Echocardiographic abnormalities in patients with COPD at their first hospital admission. Eur Respir J 2013; 41: 784-791.
7. Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 2012; 39: 945-955.
8. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43-S54.
9. Boerrigter BG, Bogaard HJ, Trip P, et al. Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest 2012; 142: 1166-1174.
10. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 189-194. (Pubitemid 40981192)
11. Boeck L, Tamm M, Grendelmeier P, et al. Acute effects of aerosolized iloprost in COPD related pulmonary hypertension: a randomized controlled crossover trial. PloS One 2012; 7: e52248.
12. Lederer DJ, Bartels MN, Schluger NW, et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD 2012; 9: 268-275.
13. Rietema H, Holverda S, Bogaard HJ, et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008; 31: 759-764.
14. Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32: 619-628.
15. McAllister DA, Maclay JD, Mills NL, et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J 2012; 39: 1097-1103.
16. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J 2012; 39: 51-58.
17. Balcells E, Antó JM, Gea J, et al. Characteristics of patients admitted for the first time for COPD exacerbation. Respir Med 2009; 103: 1293-1302.
18. Garcia-Aymerich J, Gómez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011; 66: 430-437.
19. Burgel PR, Paillasseur JL, Peene B, et al. Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PloS One 2012; 7: e51048.
20. Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010; 36: 531-539.
21. Burgel PR, Roche N, Paillasseur JL, et al. Clinical COPD phenotypes identified by cluster analysis: validation with mortality. Eur Respir J 2012; 40: 495-496.
22. Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010; 362: 217-227.
23. Grau M, Barr R, Lima JA, et al. Percent emphysema and right ventricular structure and function: the MESA Lung and MESA-RV Studies. Chest 2013 [In press DOI: 10.1378/chest.12-1779].
24. Kessler R, Faller M, Fourgaut G, et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 158-164. (Pubitemid 29036519)
25. Wells JM, Washko GR, Han MK, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 2012; 367: 913-921.
26. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155-161.